Biogen
BIIB
1,122 hedge funds and large institutions have $60B invested in Biogen in 2017 Q4 according to their latest regulatory filings, with 167 funds opening new positions, 399 increasing their positions, 384 reducing their positions, and 48 closing their positions.
248% more first-time investments, than exits
New positions opened: 167 | Existing positions closed: 48
11% more funds holding
Funds holding: 1,014 → 1,122 (+108)
4% more repeat investments, than reductions
Existing positions increased: 399 | Existing positions reduced: 384
2% more capital invested
Capital invested by funds: $59B → $60B (+$967M)
0.05% less ownership
Funds ownership: 89.15% → 89.1% (-0.05%)
26% less funds holding in top 10
Funds holding in top 10: 38 → 28 (-10)
32% less call options, than puts
Call options by funds: $989M | Put options by funds: $1.44B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$623M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
+$233M |
| 3 |
PC
PointState Capital
New York
|
+$158M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$124M |
| 5 |
JP Morgan Chase
New York
|
+$107M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$689M |
| 2 |
TCIM
TIAA CREF Investment Management
New York
|
-$232M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$161M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$156M |
| 5 |
O
OrbiMed
New York
|
-$128M |
BIIB Hedge Fund Activity: Q4 2017 in Review
1,122 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q4 2017, worth a combined $60B — up 1.6% from $59B a quarter earlier.
Buyers outnumbered sellers: 167 funds opened new BIIB positions and 48 closed out — a net gain of 119 holders — while 399 added to existing stakes and 384 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $623M. The largest seller was T. Rowe Price Associates, cutting an estimated $689M.
- 1,122 institutional investors held Biogen (BIIB) as of Q4 2017, up from 1,014 in Q3 2017.
- Funds reported $60B of Biogen stock for Q4 2017, up 1.6% quarter-over-quarter.
- 167 funds opened new Biogen positions in Q4 2017 and 48 closed out, a net change of +119 holders.
- The largest Biogen buyer in Q4 2017 was Fidelity Investments, an estimated $623M added.
- The largest Biogen seller in Q4 2017 was T. Rowe Price Associates, an estimated $689M sold.
Based on aggregated 13F filings for Q4 2017.